- Latest available (Revised)
- Original (As made)
The Human Medicines Regulations 2012, SCHEDULE 24 is up to date with all changes known to be in force on or before 20 September 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Revised legislation carried on this site may not be fully up to date. Changes and effects are recorded by our editorial team in lists which can be found in the ‘Changes to Legislation’ area. Where those effects have yet to be applied to the text of the legislation by the editorial team they are also listed alongside the legislation in the affected provisions. Use the ‘more’ link to open the changes and effects relevant to the provision you are viewing.
Whole provisions yet to be inserted into this Instrument (including any effects on those provisions):
Regulation 257
1. The name of the medicinal product.U.K.
2. The strength and pharmaceutical form of the product.U.K.
3. Where appropriate, whether the product is intended for babies, children or adults.U.K.
4. Where the product contains up to three active substances, the common name of each active substance.U.K.
5. A statement of the active substances in the product, expressed qualitatively and quantitatively per dosage unit or according to the form of administration for a given volume or weight, using their common names.U.K.
6. The pharmaceutical form and the contents by weight, by volume or by number of doses of the product.U.K.
7. A list of—U.K.
(a)where the product is injectable or is a topical or eye preparation, all excipients; or
(b)in any other case, those excipients known to have a recognized action or effect and included in the guidance [F1published under regulation 257D in the case of products for sale or supply in Great Britain, or in the case of products for sale or supply in Northern Ireland, any guidance published pursuant to Article 65 of the 2001 Directive or under regulation 257D that is applicable to such products.].
Textual Amendments
F1Words in Sch. 24 para. 7(b) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 201(2) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 155(a)); 2020 c. 1, Sch. 5 para. 1(1)
8. The method of administration of the product and if necessary the route of administration.U.K.
9. Where appropriate, space for the prescribed dose to be indicated.U.K.
10. A warning that the product must be stored out of the reach and sight of children.U.K.
11. Any special warning applicable to the product.U.K.
12. The product's expiry date (month and year), in clear terms.U.K.
13. Any special storage precautions relating to the product.U.K.
14. Any special precautions relating to the disposal of an unused product or part of a product, or waste derived from the product, and reference to any appropriate collection system in place.U.K.
15. The name and address of the holder of the [F2UK marketing authorisation, EU marketing authorisation] Article 126a authorisation or traditional herbal registration relating to the product and, where applicable, the name of the holder's representative.U.K.
Textual Amendments
F2Words in Sch. 24 para. 15 substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 201(3) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 155(b)); 2020 c. 1, Sch. 5 para. 1(1)
16. The number of the [F3UK marketing authorisation, EU marketing authorisation] Article 126a authorisation or traditional herbal registration for placing the medicinal product on the market.U.K.
Textual Amendments
F3Words in Sch. 24 para. 16 substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 201(3) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 155(b)); 2020 c. 1, Sch. 5 para. 1(1)
17. The manufacturer's batch number.U.K.
18. In the case of a product that is not a prescription only medicine, instructions for use.U.K.
[F418A. In the case of a medicinal product, other than a radiopharmaceutical, that is required by Article 54a of the 2001 Directive to bear safety features—U.K.
(a)a unique identifier which complies with the technical specifications set out in Chapter II of Commission Regulation 2016/161; and
(b)an anti-tampering device allowing verification of whether the packaging of the medicinal product has been tampered with.]
Textual Amendments
F4Sch. 24 para. 18A inserted (9.2.2019) by The Human Medicines (Amendment) Regulations 2019 (S.I. 2019/62), regs. 1, 19 and Sch. 24 para. 18A inserted (N.I.) (9.2.2019) by The Human Medicines (Amendment) Regulations 2019 (S.R. 2019/10), regs. 1, 19
19. The name of the medicinal product.U.K.
20. The strength and pharmaceutical form of the product.U.K.
21. Where appropriate, whether the product is intended for babies, children or adults.U.K.
22. Where the product contains up to three active substances, the common name of each active substance.U.K.
23. The name of the holder of the [F5UK marketing authorisation, EU marketing authorisation], Article 126a authorisation or traditional herbal registration relating to the product.U.K.
Textual Amendments
F5Words in Sch. 24 para. 23 substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 201(3) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 155(b)); 2020 c. 1, Sch. 5 para. 1(1)
24. The product's expiry date (month and year), in clear terms.U.K.
25. The manufacturer's batch number.U.K.
26. The name of the medicinal product.U.K.
27. The strength and pharmaceutical form of the product.U.K.
28. Where appropriate, whether the product is intended for babies, children or adults.U.K.
29. Where the product contains up to three active substances, the common name of each active substance.U.K.
30. The method of administration of the product and if necessary the route of administration.U.K.
31. The product's expiry date (month and year), in clear terms.U.K.
32. The manufacturer's batch number.U.K.
33. The contents of the packaging by weight, by volume or by unit.U.K.
Textual Amendments
F6Sch. 24 Pts. 4, 5 inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 201(5) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 155(d)); 2020 c. 1, Sch. 5 para. 1(1)
34. The name of the advanced therapy medicinal product which is the international non-proprietary name, or if none, the common name.
35. Where appropriate, whether the product is intended for babies, children or adults.
36. The expiry date in clear terms including the year and month and, if applicable, day.
37. A description of the active substance, expressed qualitatively and quantitatively.
38. Where the product contains tissues and cells of human or animal origin—
(a)a statement that the product contains such cells or tissues; and
(b)a short description of the cells or tissues and of their specific origin, including the species of animal in cases on non-human origin.
39. The pharmaceutical form and the contents by weight, volume or number of doses of the product.
40. A list of excipients, including preservative systems.
41. The method of use, application, administration or implantation and, if appropriate, the route of administration, with space provided for the prescribed dose to be indicated.
42. A special warning that the product is to be stored out of the sight and reach and children.
43. Any special warning necessary for the particular product.
44. Any special storage precautions.
45. Specific precautions relating to the disposal of the unused product or of waste derived from the product and, where appropriate, reference to any appropriate collection system.
46. The name and address of the holder of the UK marketing authorisation and, where applicable, the name of the representative appointed by the holder to represent him.
47. The UK marketing authorisation number.
48. The manufacturer's batch number.
49. The unique donation code assigned by a tissue establishment pursuant to—
(a)paragraph 1 of Schedule 3A to the Human Fertilisation and Embryology Act 1990, as regards human gametes and embryos; and
(b)paragraph 1 of Schedule 2 to the Human Tissue (Quality and Safety for Human Application) Regulations 2007, as regards other human tissues and cells.
50. Where the exempt advanced therapy medicinal product is for autologous use, the unique patient identifier and the words “for autologous use only”.
51. The information specified in Part 2.
52. The unique donation code assigned by a tissue establishment pursuant to—
(a)paragraph 1 of Schedule 3A to the Human Fertilisation and Embryology Act 1990, as regards human gametes and embryos; and
(b)paragraph 1 of Schedule 2 to the Human Tissue (Quality and Safety for Human Application) Regulations 2007, as regards other human tissues and cells.
53. Where the exempt advanced therapy medicinal product is for autologous use, the unique patient identifier and the words “for autologous use only”.]
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: